Ecdysterone and MK-2866 Interaction: Avoid | Peptide Database

Join others researching Clascoterone — share findings, ask questions, and learn from real experiences Clascoterone (cortexolone 17-alpha-propionate) is a first-in-class topical androgen receptor inhibitor developed by Cassiopea SpA. In August 2020, the FDA approved Winlevi (clascoterone cream 1%) for the treatment of acne vulgaris in patients aged 12 and older, making it the first new mechanism of action for acne treatment in nearly four decades and the first topical anti-androgen approved for acne in the United States. Clascoterone is also under development as Breezula (clascoterone solution 7.5%) for androgenetic alopecia, where it has completed Phase 3 clinical trials. The compound works by competitively inhibiting androgen receptor activation at the site of application -- the sebaceous gland for acne and the hair follicle for androgenetic alopecia -- without producing the systemic anti-androgenic effects associated with oral anti-androgens such as spironolactone or cyproterone acetate. Its steroidal structure allows it to fit precisely into the androgen receptor binding pocket, and its rapid local metabolism to cortexolone (an inactive metabolite) limits systemic exposure. This pharmacological profile makes clascoterone suitable for use in both men and women, unlike systemic anti-androgens which carry risks of feminization in male patients. Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target tissues -- sebaceous glands (for acne) and dermal papilla cells of hair follicles (for alopecia). By occupying the AR binding site, clascoterone prevents dihydrotestosterone (DHT) and testosterone from activating the receptor and initiating the downstream signaling cascade that drives sebum overproduction and hair follicle miniaturization. Structurally, clascoterone is a synthetic derivative of cortexolone (11-deoxycortisol), modified with a 17-alpha-propionate ester. This structural design serves two purposes: the steroidal backbone provides high binding affinity for the androgen receptor, while the ester group is rapidly cleaved by local esterases in the skin, converting clascoterone to cortexolone, which has negligible androgen receptor binding. This built-in metabolic inactivation ensures that any compound reaching systemic circulation is pharmacologically inactive, confining the anti-androgenic effect to the treatment site. In clinical studies, clascoterone showed no meaningful impact on systemic hormone levels including testosterone, DHT, luteinizing hormone, or follicle-stimulating hormone at therapeutic doses, confirming its local mechanism of action.

Join others researching Metformin — share findings, ask questions, and learn from real experiences Metformin is a biguanide compound and the most widely prescribed oral medication for type 2 diabetes mellitus worldwide, with over 150 million prescriptions annually. Originally derived from the French lilac (Galega officinalis), metformin was introduced in clinical practice in the 1950s in Europe and received FDA approval in the United States in 1995. Beyond its well-established role in glucose regulation, metformin has attracted significant attention in longevity and aging research. The Targeting Aging with Metformin (TAME) trial, a landmark multi-center study, is investigating whether metformin can delay the onset of age-related diseases in non-diabetic older adults. Observational data have suggested that diabetic patients taking metformin may have lower all-cause mortality than age-matched non-diabetic controls, prompting serious scientific interest in its potential geroprotective properties. Metformin exerts its primary effects through activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK activation triggers a cascade of downstream metabolic improvements: enhanced glucose uptake in skeletal muscle, suppression of hepatic gluconeogenesis, improved mitochondrial function, and increased fatty acid oxidation. Metformin also inhibits Complex I of the mitochondrial electron transport chain, which contributes to its AMPK-activating effects by increasing the AMP-to-ATP ratio. Beyond glucose metabolism, metformin modulates several pathways implicated in aging, including inhibition of mTOR signaling (a key regulator of cellular growth and senescence), reduction of oxidative stress and reactive oxygen species, attenuation of chronic low-grade inflammation via NF-kB pathway suppression, and activation of autophagy. These pleiotropic mechanisms underpin both its antidiabetic efficacy and its potential as an anti-aging compound.